A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors June 15, 2017 Sponsor Seattle Genetics Protocol Number Seattle Genetics SGN2FF-001 To Learn More Call 201-510-0910
